Product Description
Recombinant Microbial Lipase
Mechanisms of Action: N/A
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Solvay Pharm
Company Location: 1120 BRUSSELS C9 00000
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Exocrine Pancreatic Insufficiency|Pancreatitis, Chronic
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
S339.2.001 | P2 |
Terminated |
Exocrine Pancreatic Insufficiency|Pancreatitis, Chronic |
2009-03-01 |
|
2007-000375-42 | P2 |
Completed |
Pancreatitis, Chronic|Exocrine Pancreatic Insufficiency |
2008-08-21 |